Sobi to refinance existing credit facility

Sobi has decided to refinance its existing credit facility either by issuing a
SEK denominated bond up to SEK 500 M or by entering into a new revolving credit
facility with SEB and Nordea.

The purpose of the refinancing is to improve the financial flexibility and to
extend the maturity profile. The refinancing will replace existing bank debt and
will not increase Sobi's total debt.

Sobi has appointed Nordea as Joint Bookrunner and Co-ordinator together with SEB
as Joint Bookrunner to investigate a bond issue. The lead banks Nordea and SEB
have committed to provide a credit facility in a corresponding amount in the
event that Sobi does not proceed with the bond issue.



For further information, please contact:
Lars Sandström, CFO
Tel.: +46 8 697 26 33



Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to bringing
innovative therapies and services to improve the health of rare disease patients
and their families. The product portfolio comprises about 45 marketed products
as well as projects in the late clinical phase. Key therapeutic areas are
Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK 1.9
billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.



The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information was
released for public distribution on 5 June 2012 at 16.50 CET.